Cadrenal TherapeuticsCVKD
13F holders, Q4 2024 (December 31)9holders +7
7new positions
1sold out
$14.49avg. 13F price*
At the end of Q4 2024, 9 institutions reported holding Cadrenal Therapeutics Inc. (CVKD) in their 13F filings, up 7 from Q3 2024. 7 opened new positions and 1 sold out. The largest holders were Geode Capital Management, LLC ($153K), UBS Group AG ($31K) and Morgan Stanley ($17K).
- Company
- Cadrenal Therapeutics Inc.
- CUSIP
- 127636207
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 7 | $214K |
| Exits | 1 | $0 |
All 13F filers, Q3 2024 → Q4 2024: 14,800 shares bought and 25 shares sold, net +14,775 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Geode Capital Management, LLC | 0.00% | New | 10,554 | $153K |
| UBS Group AG | 0.00% | New | 2,172 | $31K |
| Morgan Stanley | 0.00% | New | 1,146 | $17K |
| Osaic Holdings, Inc. | 0.00% | New | 500 | $7K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 368 | $5K |
| R Squared Ltd | 0.00% | — | 40 | $580 |
| Archer Investment Corp | 0.00% | New | 35 | $507 |
| Carolina Wealth Advisors, LLC | 0.00% | New | 20 | $290 |
| Bank of America Corp. | 0.00% | Add +100.0% | 10 | $145 |
"% of holder's portfolio" is CVKD's weight in each manager's 13F, not the share of Cadrenal Therapeutics Inc. the manager owns.